Ann Conkle
Mar 2, 2012

Drugs: 'New' does not always mean 'better'

Cases in which a newly approved drug is more effective than the cheaper alternatives already available are the exceptions rather than the rule. This is the conclusion reached in new study in the current issue of Deutsches Ärzteblatt International, the German Medical Association's official international bilingual science journal. Research into 39 proprietary medicinal products (PMPs) launched on the German market in 2009 and 2010 shows that there were frequently insufficient data available on efficacy when approval was granted. The legal requirements of the licensing procedure have never yet required direct data comparing a new drug to a commercially available drug. The researchers' evaluations also show that for around half of approvals the only trials presented compared the new drug with a placebo, not an effective comparator drug, meaning that new PMPs may actually be inferior to the alternatives already on the market.

0 Comments
Related Articles
Valerie Clark
Feb 6, 2012
Open call for innovation gives everyone a voice in clinical study design
Transparency Life Sciences, LLC (TLS), a new drug development company, has launched a thoroughly innovative platform for clinical studies, with... Read More
Valerie Clark
Feb 24, 2012
FDA criticized for not approving medical devices fast enough
Recent news reports attacking the US drug approval process are not considering all the facts. The Food and Drug Administration... Read More
Jeff Herman
Mar 1, 2012
Industry and academia: Not so strange bedfellows
The nature of research, biomedical and otherwise, is changing forever. I can’t predict the exact time it will happen, but,... Read More